ERBB2 and gastric cancer: For comparison, in prior analyses in HER2-positive patients with advanced gastric cancer, trastuzumab plus chemotherapy extended Q-TWiST by 2.42 months compared with chemotherapy alone[22], while recently trastuzumab deruxtecan was also estimated to extend quality-adjusted survival by 0.9 months compared to chemotherapy (6.6 vs 5.7 months) over 10 months of follow-up [23].